Nivolumab plus ipilimumab for treatment-naïve metastatic uveal melanoma: An open-label, multicenter, phase II trial by the spanish multidisciplinary melanoma group (GEM-1402)
Keywords:
Nivolumab (nivo)
Plus ipilimumab (ipi)
First-line therapy
Overall survival (OS)
Citation:
Piulats, J.M. (José María); Espinosa, E. (Enrique); Cruz-Merino, L. (Luis) de la; et al. "Nivolumab plus ipilimumab for treatment-naïve metastatic uveal melanoma: An open-label, multicenter, phase II trial by the spanish multidisciplinary melanoma group (GEM-1402)". Journal of clinical oncology. 39 (6), 2020, 586 - 598
Statistics and impact
0 citas en
0 citas en
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.